Literature DB >> 31978577

Nocardia bacteremia: A single-center retrospective review and a systematic review of the literature.

Eloise Williams1, Adam W Jenney2, Denis W Spelman2.   

Abstract

OBJECTIVES: Nocardia bacteremia is a rare but severe disease associated with high mortality. This systematic review is the largest and most comprehensive review performed over the past 20 years.
METHODS: A single-center retrospective review of Nocardia bacteremia was performed using hospital microbiology records from January 1, 2010 to December 31, 2017. A systematic literature review was also performed to identify cases of Nocardia bacteremia described in the NCBI PubMed database in English between January 1, 1999 and December 31, 2018.
RESULTS: Four new cases of Nocardia bacteremia are described. The systematic review identified 134 cases with sufficient information available for analysis. Of the total 138 cases, the median age was 58 years (interquartile range (IQR) 44-69 years) and 70% were male. Eighty-one percent were immunocompromised (corticosteroid use (49%), hematological malignancy (20%), solid organ transplant (20%), solid organ malignancy (19%), and hematopoietic stem cell transplantation (15%)) and 29% had endovascular devices. Pulmonary infection was the most common concurrent site of clinical disease (67%). The median incubation time to the detection of Nocardia bacteremia was 4 days (IQR 3-6 days). Blood cultures were the only positive microbiological specimen in 38% of cases. The median total duration of treatment was 75 days (IQR 25-182 days). Thirty-day all-cause mortality was 28% and overall all-cause mortality was 40%.
CONCLUSIONS: Nocardia bacteremia is most frequently identified in immunocompromised patients and those with intravascular devices. Although rare, it represents a serious infection with high associated overall mortality.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Bacteremia; Central line-associated bloodstream infection; Immunocompromise; Nocardia; Nocardiosis

Year:  2020        PMID: 31978577     DOI: 10.1016/j.ijid.2020.01.011

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  7 in total

1.  Nocardia Infections in the Immunocompromised Host: A Case Series and Literature Review.

Authors:  Emanuele Palomba; Arianna Liparoti; Anna Tonizzo; Valeria Castelli; Laura Alagna; Giorgio Bozzi; Riccardo Ungaro; Antonio Muscatello; Andrea Gori; Alessandra Bandera
Journal:  Microorganisms       Date:  2022-05-29

2.  [Bacteriemia by disseminated pulmonary nocardiosis].

Authors:  E Lepe-Balsalobre; R Rubio-Sánchez; R Cabra-Rodríguez
Journal:  Rev Esp Quimioter       Date:  2021-07-07       Impact factor: 1.553

3.  Epidemiology and Antimicrobial Resistance Profiles of the Nocardia Species in China, 2009 to 2021.

Authors:  Hao Wang; Yue Zhu; Qiaozhen Cui; Wenming Wu; Gang Li; Dongke Chen; Lili Xiang; Jiuxin Qu; Dongyan Shi; Binghuai Lu
Journal:  Microbiol Spectr       Date:  2022-03-02

4.  Brain metastasis or nocardiosis? A case report of central nervous system Nocardiosis with a review of the literature.

Authors:  Hojin Sun; Mariam Goolam Mahomed; Jaimin Patel
Journal:  J Community Hosp Intern Med Perspect       Date:  2021-03-23

5.  Cushing's Syndrome With Nocardiosis: A Case Report and a Systematic Review of the Literature.

Authors:  Da Zhang; Yan Jiang; Lin Lu; Zhaolin Lu; Weibo Xia; Xiaoping Xing; Hongwei Fan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-29       Impact factor: 5.555

6.  Use of Continuous Etomidate Infusion to Rapidly Correct Hypercortisolism in a Patient With Disseminated Nocardiosis.

Authors:  Azka Tasleem; Melissa Cavaghan; Quinn A Czosnowski; Zeb Saeed
Journal:  Cureus       Date:  2021-12-06

7.  Nocardia Infection in Nephrotic Syndrome Patients: Three Case Studies and A Systematic Literature Review.

Authors:  Yan Cheng; Tian-Yi Wang; Hong-Li Yuan; Wei Li; Jing-Ping Shen; Zheng-Xin He; Jing Chen; Jie-Ying Gao; Fu-Kun Wang; Jiang Gu
Journal:  Front Cell Infect Microbiol       Date:  2022-01-24       Impact factor: 5.293

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.